News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

The Power of Partnership; "A Three-Fold Increase In The Capacity To Care For People Living With HIV/AIDS And Other Infectious Diseases, At The Makerere University In Uganda, Will Bring Benefits Across All of Africa" - Pfizer Inc. (PFE) Chairman And CEO, Hank McKinnel

10/19/2005 5:11:53 PM

KAMPALA, Uganda, Oct. 20 /PRNewswire-FirstCall/ -- Pfizer Inc is pleased to announce its continued involvement and commitment to the Infectious Diseases Institute(IDI) which officially opens it doors today on the grounds of the Makerere University in Uganda. The fully operational facility will have major implications for patients and physicians in sub-Saharan Africa and fits well with Pfizer's other partnership and philanthropic programs around the globe.

Pfizer and the Pfizer Foundation have already contributed over $15 million USD to the establishment of the Infectious Diseases Institute.

Dr. McKinnell said, "The Infectious Diseases Institute marks a dramatic advance in addressing the public health needs of sub-Saharan Africa. As Pfizer, we are committed to improving the lives of people through partnerships such as this, our innovative products, the company's pipeline and various philanthropy initiatives around the globe."

Pfizer's Role in Establishing the IDI * Pfizer has been instrumental in establishing the Academic Alliance for AIDS Care and Prevention, recruiting other organizations to help establish the IDI, and coordinating operational aspects of facility construction and equipping. * Pfizer has contributed a wide range of other resources to ensure the program's success, including engineering and IT support, global manufacturing support, legal services, procurement and shipping services, donations of Pfizer's antifungal medicine Diflucan(R), fundraising and organizational assistance, the skills and energy of individual Pfizer employees such as the Global Health Fellows.

Editor's note: For a full program description of the IDI, see accompanying press release issued by the Infectious Diseases Society.

In addition to the IDI, Pfizer is involved in other public/private partnerships. In 2003, Pfizer's philanthropic efforts totalled nearly $700 million -- more than $2 million per day.

Pfizer's Global Philanthropy Programs The Diflucan Partnership Program * Diflucan is made available free of charge through government hospitals and nongovernmental organizations to patients who are often lacking even the most basic healthcare. * Over 915 facilities in 23 countries have been involved in the program to-date, treating over 87,000 patients for life-threatening fungal infections. * The Diflucan Partnership Program also trains healthcare workers -- more than 18,000 healthcare providers to-date -- in partnership with the International Association of Physicians in AIDS Care. The Global Health Fellows Program * The Fellows program, started in 2003, places Pfizer colleagues for up to six months in fully paid assignments with NGOs and other organizations to provide all levels of assistance in fighting the pandemic. * Fellows span the range of disciplines at Pfizer including epidemiologists, physicians, IT experts and supply-chain coordinators. The International HIV/AIDS Grants program * Since 2002, the Pfizer Foundation has awarded $5 million to 40 organizations. * The grants focus on HIV training and capacity building in Caribbean, African and Asian countries. Southern HIV/AIDS Prevention Initiative * The Pfizer Foundation started this Initiative in nine states in the United States with rising rates of HIV infection (Florida, Georgia, North Carolina, South Carolina, Texas, Tennessee, Mississippi, Alabama and Louisiana) * The Initiative funded 24 community-based organizations in 2003 and will award additional grants over the next two years. * Grants up to $50,000 per organization are designed to serve high affected populations, such as multi-cultural women in low-income communities. The International Trachoma Initiative * Pfizer Inc is dedicated to eliminating blinding trachoma, the world's leading cause of preventable blindness. * The effectiveness of a single annual dose of Zithromax in halting infection has significantly accelerated progress toward elimination. * ITI is currently active in eleven countries: Ethiopia, Ghana, Mali, Mauritania, Morocco, Nepal, Niger, Senegal, Sudan, Tanzania, and Vietnam. * To date, ITI has provided support for nearly 120,000 sight-saving surgeries and distributed over 16.5 million antibiotic treatments.

Chuck Hardwick, head of the Pfizer Foundation and senior vice president, Pfizer Inc said, "Many people within Pfizer, with different expertise and skills, have put in a tremendous amount of time and effort to make today's IDI opening a reality. Their hard work, together with that of our esteemed partners, means that patients and their families stand to benefit from all of us working together."

Photo: A free corporate logo to accompany this story is availableimmediately via Wieck Photo Database to any media with telephoto receiver orelectronic darkroom, PC or Macintosh, that can accept overhead transmissions.To retrieve a logo, please call 972-392-0888. Pfizer Inc

CONTACT: Imraan Munshi, +90-532-467-9904, or +256-0-78-663-293, forPfizer Inc

Company News On-Call: Pfizer's press releases are available through PRNewswire's Company News On-Call service on PRN's Web Site. Visit

Company News On-Call:

Read at

comments powered by Disqus